ICUINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ICU MEDICAL INC/DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$161.24−1.75 (-1.07%)
Close on Oct 19, 2026
- Market cap
- $4.04B
- P/E (TTM)
- 134.4
- Dividend yield
- –
ICU MEDICAL INC/DE revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infusion Consumables [Member] | $1.11B | $1.04B | $969.13M | $974.99M | $555.19M | $473.74M | $477.61M | $483.04M | $365.67M | $324.87M | 49.7% | +6.8% |
| Infusion Systems [Member] | $684.21M | $652.41M | $629.04M | $617.44M | $352.32M | $359.69M | $328.28M | $355.48M | $290.21M | $0 | 30.7% | +4.9% |
| Vital Care | $437.92M | $690.77M | $660.95M | $687.57M | $408.80M | $0 | – | – | – | – | 19.6% | -36.6% |
| Other Revenue [Member] | – | – | – | – | – | – | $0 | $0 | $64.82M | $903.00K | – | – |
| Critical Care [Member] | – | – | – | $47.33M | $49.32M | $48.60M | $45.34M | $53.53M | $49.96M | $53.60M | – | – |
| IV Solutions [Member] | – | – | – | $363.47M | $359.48M | $388.97M | $414.97M | $507.99M | $521.96M | $0 | – | – |
| Product [Member] | – | – | – | – | – | – | $1.27B | $1.40B | $1.29B | $379.34M | – | – |
| Product and Service, Other [Member] | – | – | – | – | – | – | $0 | $0 | $447.00K | $33.00K | – | – |
| Infusion Consumables-Smiths Medical | – | – | – | $340.12M | $0 | $0 | – | – | – | – | – | – |
| Vascular Access | – | – | – | $326.77M | $0 | $0 | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.36B | $1.53B | $1.44B | $1.46B | $941.81M | $910.63M | $923.34M | $1.05B | $980.04M | $261.69M | 60.8% | -11.5% |
| EMEA [Member] | $411.68M | $393.53M | $373.57M | $367.41M | $147.49M | $132.76M | $130.53M | $134.36M | $119.93M | $50.11M | 18.5% | +4.6% |
| APAC | $232.90M | $232.82M | $241.70M | $257.21M | $85.69M | $79.61M | – | – | – | – | 10.4% | +0.0% |
| Other foreign countries [Member] | $230.56M | $223.59M | $203.84M | $195.31M | $141.32M | $148.00M | $212.34M | $211.00M | $192.64M | $67.57M | 10.3% | +3.1% |
| Canada | – | – | – | – | – | – | – | – | $69.75M | $16.27M | – | – |
| Foreign | – | – | – | – | $374.50M | $360.38M | $342.87M | $345.36M | $312.57M | $117.68M | – | – |
| Other LATAM | – | – | – | – | – | – | – | – | $57.85M | $29.92M | – | – |
| Asia Pacific | – | – | – | – | – | – | – | – | $54.47M | $10.30M | – | – |
| Europe | – | – | – | – | – | – | – | – | $100.42M | $50.11M | – | – |
From the segment and revenue-disaggregation notes of Icu Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.